Comprehensive Analysis Identifies PI3K/Akt Pathway Alternations as an Immune-Related Prognostic Biomarker in Colon Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitor Treatment.

Anqi Lin Tianqi Gu Xigang Hu Jian Zhang Peng Luo

Published in: Journal of immunology research (2022)

PI3K/Akt pathway mutation status can be used as an independent predictor of response to ICI treatment in COAD patients. PI3K/Akt mutations are correlated with improved OS, higher immunogenicity, greater immune response scores, and increases in activated immune cells.

Keyphrases

pi k akt
immune response
signaling pathway
cell proliferation
squamous cell carcinoma
ejection fraction
genome wide
radiation therapy
dendritic cells
cell cycle arrest
gene expression
inflammatory response
patient reported outcomes
toll like receptor
chronic kidney disease
cell death